Fig. 2
From: A feasibility of computational drug screening for Fuchs endothelial corneal dystrophy
L1000FWD-based visualization of drug candidates for FECD gene expression reversal. (A) Drug landscape visualization generated by L1000FWD analysis of differentially expressed genes (DEGs) from FECD patients with TCF4 trinucleotide repeat expansion (TNR > 50) compared to non-FECD subjects (706 upregulated and 962 downregulated genes). The plot displays 16,849 compounds clustered by their mode of action (MOA), represented by the different colors indicated in the legend. The shape of each plot represents the duration of drug exposure (Time) in the corresponding cell line (6, 24, or 48 h) as shown in the legend. (B) Score-based visualization of 10,655 identified drug candidates. The color gradient represents the compound effects on FECD-associated gene expression, where blue indicates reversers (compounds that normalize dysregulated gene expression toward the expression observed in non-FECD patterns) and red indicates mimickers (compounds that enhance FECD-associated expression patterns). The color intensity corresponds to the magnitude of effect ( −0.13 to 0.11). These visualizations were generated by the authors using the L1000FWD web-based tool ( https://maayanlab.cloud/L1000FWD/ ), which is freely available for academic research under open access principles. The visualizations shown are direct outputs from our analysis using this tool and are displayed under academic fair use principles and in accordance with the tool’s terms of use.
